Friday 23 September 2016

Human Immunodeficiency Virus (HIV) - Japan Drug Forecast and Market Analysis to 2023 including epidemiology, etiology, symptoms, diagnosis, pathology

ResearchMoz added Latest Research Report titled " Human Immunodeficiency Virus (HIV) - Japan Drug Forecast and Market Analysis to 2023 " to it's Large Report database.

Human Immunodeficiency Virus (HIV) - Japan Drug Forecast and Market Analysis to 2023

Summary

Human immunodeficiency virus (HIV) is a retrovirus that infects the cells of the immune system, destroying or impairing their function. As the infection progresses, the immune system becomes increasingly weaker, making the infected person more susceptible to other infections. Since the first anti-HIV drug, GlaxoSmithKlines (GSKs) Retrovir (azidothymidine), was approved in 1987, major improvements have been made in the field of antiretroviral therapy (ART). This rapid progress has been headlined by the emergence of once-daily, single-tablet regimens (STRs) such as Gilead Science's Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]), which offer patients an unparalleled level of convenience.

Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=816337

The Japanese HIV market also differs from that of the US and the 5EU in that the uptake of STRs has been less pronounced. For example, Atripla, which has become a leading HIV drug across the 6MM, is not currently licensed in Japan. Gileads Stribild, an INI-based STR that was approved by the FDA in August 2012, became the first STR to be licensed in Japan, in early 2013 (Japan Tobacco, press release, March 25, 2013).

Scope

- Overview of Human Immunodeficiency Virus (HIV) including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the Japan including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the Japan from 2013-2023.
- Analysis of the impact of key events as well the drivers and restraints affecting the Japan Human Immunodeficiency Virus (HIV) market.

Read All Pharmaceutical Market Research Reports @ http://www.researchmoz.us/pharmaceutical-market-reports-38.html

Table of Contents

1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 12
2 Introduction 13
2.1 Catalyst 13
2.2 Related Reports 14
2.3 Upcoming Related Reports 14
3 Disease Overview 15
3.1 Etiology 15
3.1.1 Viral Lifecycle 15
3.2 Pathophysiology 18
3.3 Staging and Symptoms 19
3.3.1 Primary or Acute Infection 19
3.3.2 Chronic Infection 20
3.3.3 Advanced Infection/AIDS 20
3.4 Prognosis 22
3.5 Quality of Life 22
4 Disease Management 24
4.1 Diagnosis and Treatment Overview 24
4.1.1 Screening and Diagnosis 24
4.1.2 Treatment Guidelines and Leading Prescribed Drugs 25
4.1.3 Clinical Practice 27
US Key Opinion Leader 27
4.2 Japan 38
4.2.1 Screening and Diagnosis 39
4.2.2 Clinical Practice 39

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket
Albany NY, United States - 12207
Tel: +1-518-621-2074 / Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG

No comments:

Post a Comment